In many solid tumor malignancies, including breast cancer, lung, head and neck cancer, and melanoma, increased activity within the PI3K pathway occurs through activating mutations and gene amplifications in PIK3CA (PI3K-α), or loss of expression of the PI3K tumor suppressor, PTEN (8–15). This evidence concerns the gene PIK3CB and head and neck cancer.